Literature DB >> 2253676

Pharmacokinetics of various single intravenous and oral doses of omeprazole.

T Andersson1, C Cederberg, C G Regårdh, I Skånberg.   

Abstract

The influence of dose on the kinetics of omeprazole and two of its metabolites, hydroxyomeprazole and the sulphone, has been studied. Ten healthy subjects were given omeprazole 10 and 40 mg iv and 10, 40 and 90 mg orally. No significant dose-related difference in any parameter calculated from the iv experiments was detected. Following the oral solutions, however, there was a dose-dependent increase in systemic availability, probably due to saturable first-pass elimination. The AUC of the sulphone also seemed to increase non-linearly with increasing dose, and that of the hydroxyomeprazole increased in proportion to dose. The slight dose-dependency of the bioavailability of the solution is considered to be of no or limited clinical relevance. Furthermore, since omeprazole is given orally as slowly absorbed enteric coated granules in the dose of 20 mg o.d., the potential for dose-dependent kinetics in clinical practice would be much less than in the present study.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253676     DOI: 10.1007/bf00280061

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Fully automated gradient elution liquid chromatographic assay of omeprazole and two metabolites.

Authors:  I Grundevik; G Jerndal; K Balmér; B A Persson
Journal:  J Pharm Biomed Anal       Date:  1986       Impact factor: 3.935

2.  The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.

Authors:  B Wallmark; P Lorentzon; H Larsson
Journal:  Scand J Gastroenterol Suppl       Date:  1985

3.  The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.

Authors:  C G Regårdh; T Andersson; P O Lagerström; P Lundborg; I Skånberg
Journal:  Ther Drug Monit       Date:  1990-03       Impact factor: 3.681

4.  Biliary excretion of intravenous [14C] omeprazole in humans.

Authors:  T Lind; T Andersson; I Skånberg; L Olbe
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

5.  Identification of two main urinary metabolites of [14C]omeprazole in humans.

Authors:  L Renberg; R Simonsson; K J Hoffmann
Journal:  Drug Metab Dispos       Date:  1989 Jan-Feb       Impact factor: 3.922

6.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

7.  Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.

Authors:  P O Lagerström; B A Persson
Journal:  J Chromatogr       Date:  1984-08-10

8.  Pharmacokinetics and metabolism of omeprazole in animals and man--an overview.

Authors:  C G Regårdh; M Gabrielsson; K J Hoffman; I Löfberg; I Skånberg
Journal:  Scand J Gastroenterol Suppl       Date:  1985

9.  Pharmacokinetics and metabolism of omeprazole in man.

Authors:  C G Regårdh
Journal:  Scand J Gastroenterol Suppl       Date:  1986

10.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Authors:  T Lind; C Cederberg; G Ekenved; U Haglund; L Olbe
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

  10 in total
  13 in total

1.  Pharmacokinetic study of omeprazole in elderly healthy volunteers.

Authors:  S Landahl; T Andersson; M Larsson; B Lernfeldt; P Lundborg; C G Regårdh; E Sixt; I Skånberg
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.

Authors:  Tsukasa Uno; Takenori Niioka; Makoto Hayakari; Norio Yasui-Furukori; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Eur J Clin Pharmacol       Date:  2007-01-04       Impact factor: 2.953

Review 3.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

4.  Population pharmacokinetics of omeprazole in a random Iranian population.

Authors:  Shahran Ala; Fatemeh Zanad; Mohammad Reza Shiran
Journal:  Caspian J Intern Med       Date:  2013

5.  Pharmacokinetics of paracetamol in Göttingen minipigs: in vivo studies and modeling to elucidate physiological determinants of absorption.

Authors:  Claudia Suenderhauf; Gerald Tuffin; Helle Lorentsen; Hans-Peter Grimm; Christophe Flament; Neil Parrott
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

6.  Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.

Authors:  C H Wilder-Smith; H U Bettschen; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

7.  Pharmacokinetics of intravenous omeprazole in children.

Authors:  E Jacqz-Aigrain; M Bellaich; C Faure; J Andre; P Rohrlich; V Baudouin; J Navarro
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis.

Authors:  T Andersson; R Olsson; C G Regårdh; I Skånberg
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

9.  A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.

Authors:  Min Ye; Swati Nagar; Ken Korzekwa
Journal:  Biopharm Drug Dispos       Date:  2016-04       Impact factor: 1.627

Review 10.  Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders.

Authors:  W Creutzfeldt
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.